Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Glass cell carcinoma of cervix Indication Strategy Report 2026: PD-1, Trials and Deals
30 July 2026
2026 Glass cell carcinoma of cervix indication strategy covering epidemiology, PD-1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Adenomatoid tumor Indication Strategy Report 2026: WT1, Trials and Deals
30 July 2026
2026 Adenomatoid tumor indication strategy covering epidemiology, WT1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
High-grade endometrial stromal sarcoma Indication Strategy Report 2026: YWHAE-NUTM2, Trials and Deals
30 July 2026
2026 High-grade endometrial stromal sarcoma indication strategy covering epidemiology, YWHAE-NUTM2 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Uterine adenosarcoma Indication Strategy Report 2026: CDK4, Trials and Deals
30 July 2026
2026 Uterine adenosarcoma indication strategy covering epidemiology, CDK4 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Juvenile granulosa cell tumor Indication Strategy Report 2026: AKT1, Trials and Deals
30 July 2026
2026 Juvenile granulosa cell tumor indication strategy covering epidemiology, AKT1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Sex cord tumor with annular tubules Indication Strategy Report 2026: STK11, Trials and Deals
30 July 2026
2026 Sex cord tumor with annular tubules indication strategy covering epidemiology, STK11 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Spermatocytic tumor Indication Strategy Report 2026: DMRT1, Trials and Deals
30 July 2026
2026 Spermatocytic tumor indication strategy covering epidemiology, DMRT1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Embryonal carcinoma Indication Strategy Report 2026: KIT, Trials and Deals
30 July 2026
2026 Embryonal carcinoma indication strategy covering epidemiology, KIT biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Extragonadal germ cell tumor Indication Strategy Report 2026: KIT, Trials and Deals
30 July 2026
2026 Extragonadal germ cell tumor indication strategy covering epidemiology, KIT biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Mediastinal germ cell tumor Indication Strategy Report 2026: KIT, Trials and Deals
30 July 2026
2026 Mediastinal germ cell tumor indication strategy covering epidemiology, KIT biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Pulmonary blastoma Indication Strategy Report 2026: DICER1, Trials and Deals
30 July 2026
2026 Pulmonary blastoma indication strategy covering epidemiology, DICER1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Intimal sarcoma Indication Strategy Report 2026: MDM2, Trials and Deals
30 July 2026
2026 Intimal sarcoma indication strategy covering epidemiology, MDM2 biology, active trials, transactions, unmet need, competition and market attractiveness.